PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic spontaneous urticaria (CSU) is a common condition treated by allergist/immunologists, but the only FDA-approved biologic medication, omalizumab, may be underutilized globally.
UNASSIGNED: This study was performed to determine the global prescription of omalizumab for treatment of CSU by allergists/immunologists.
UNASSIGNED: Anonymous questionnaire surveys were distributed online to World Allergy Organization (WAO) members worldwide. Categorical data were analyzed for descriptive analysis using one-way frequency tabulation in SAS 9.4.
UNASSIGNED: There were 348 respondents (43 missing data); Average age 51 (range 28-90); M/F 48%/52%. 58% had > 15 years of clinical experience and 10% < 5; 42% worked in private clinics, 36% public hospitals, 24% academia, 18% private hospitals, and 4% in community practice. Eighty-two percent (82%) prescribed omalizumab for CSU patients and use of omalizumab was highest among young practitioners. The most significant barriers were cost (63%) and restricted formulary (24%). Drug safety (63%) and chances of adverse events (47%) were the most significant factors deciding treatment. Twenty-two percent (22%) reported 80-100% of CSU patients were complete responders to omalizumab; 34% preferred increasing frequency (q 2-weeks), and 18% preferred increasing dose (600 mg q 4-weeks) for partial or non-responders. UAS7, UCT, and CU-QoL were used to assess CSU by 55%, 29%, and 25% of respondents, respectively. Autoimmune thyroid disease (62%), thyroid abnormality (43%) and allergic rhinitis (35%) were the most frequent comorbidities reported.
UNASSIGNED: Most clinicians favored omalizumab over other potential treatments due to safety. Although younger clinicians were more likely to prescribe omalizumab, cost and formulary access were major barriers. Only 22% of respondents reported 80% or greater of their patients had complete response to omalizumab, indicating the need for novel CSU therapies.
UNASSIGNED: This study was performed to determine the global prescription of omalizumab for treatment of CSU by allergists/immunologists.
UNASSIGNED: Anonymous questionnaire surveys were distributed online to World Allergy Organization (WAO) members worldwide. Categorical data were analyzed for descriptive analysis using one-way frequency tabulation in SAS 9.4.
UNASSIGNED: There were 348 respondents (43 missing data); Average age 51 (range 28-90); M/F 48%/52%. 58% had > 15 years of clinical experience and 10% < 5; 42% worked in private clinics, 36% public hospitals, 24% academia, 18% private hospitals, and 4% in community practice. Eighty-two percent (82%) prescribed omalizumab for CSU patients and use of omalizumab was highest among young practitioners. The most significant barriers were cost (63%) and restricted formulary (24%). Drug safety (63%) and chances of adverse events (47%) were the most significant factors deciding treatment. Twenty-two percent (22%) reported 80-100% of CSU patients were complete responders to omalizumab; 34% preferred increasing frequency (q 2-weeks), and 18% preferred increasing dose (600 mg q 4-weeks) for partial or non-responders. UAS7, UCT, and CU-QoL were used to assess CSU by 55%, 29%, and 25% of respondents, respectively. Autoimmune thyroid disease (62%), thyroid abnormality (43%) and allergic rhinitis (35%) were the most frequent comorbidities reported.
UNASSIGNED: Most clinicians favored omalizumab over other potential treatments due to safety. Although younger clinicians were more likely to prescribe omalizumab, cost and formulary access were major barriers. Only 22% of respondents reported 80% or greater of their patients had complete response to omalizumab, indicating the need for novel CSU therapies.
摘要：
■慢性自发性荨麻疹（CSU）是由过敏症/免疫学家治疗的常见病症，但唯一的FDA批准的生物药物，奥马珠单抗，可能在全球范围内没有得到充分利用。
■这项研究是为了确定变态反应学家/免疫学家对奥马珠单抗治疗CSU的总体处方。
■匿名问卷调查在线分发给世界各地的世界过敏组织（WAO）成员。使用SAS9.4中的单向频率表分析分类数据以进行描述性分析。
■有348名受访者（43个缺失数据）；平均年龄51岁（范围28-90）；M/F48%/52%。58%的人有>15年的临床经验，10%<5年；42%的人在私人诊所工作，36%公立医院，24%的学术界，18%的私立医院，在社区实践中占4%。82％（82％）的CSU患者使用奥马珠单抗，在年轻从业者中使用奥马珠单抗最高。最重要的障碍是成本(63%)和限制性处方(24%)。药物安全性（63％）和不良事件发生率（47％）是决定治疗的最重要因素。22％（22％）的CSU患者报告80-100％是奥马珠单抗的完全缓解者；34％的患者倾向于增加频率（q2周），对于部分或无反应者，18%的人优选增加剂量(600毫克每4周)。UAS7,UCT,和CU-QoL用于评估CSU的55%，29%,25%的受访者，分别。自身免疫性甲状腺疾病（62%），甲状腺异常(43%)和过敏性鼻炎(35%)是最常见的合并症.
■由于安全性，大多数临床医生偏爱奥马珠单抗而不是其他潜在的治疗方法。尽管年轻的临床医生更有可能开出奥马珠单抗，成本和处方是主要障碍。只有22%的受访者报告80%或更多的患者对奥马珠单抗有完全缓解，表明需要新的CSU疗法。
■这项研究是为了确定变态反应学家/免疫学家对奥马珠单抗治疗CSU的总体处方。
■匿名问卷调查在线分发给世界各地的世界过敏组织（WAO）成员。使用SAS9.4中的单向频率表分析分类数据以进行描述性分析。
■有348名受访者（43个缺失数据）；平均年龄51岁（范围28-90）；M/F48%/52%。58%的人有>15年的临床经验，10%<5年；42%的人在私人诊所工作，36%公立医院，24%的学术界，18%的私立医院，在社区实践中占4%。82％（82％）的CSU患者使用奥马珠单抗，在年轻从业者中使用奥马珠单抗最高。最重要的障碍是成本(63%)和限制性处方(24%)。药物安全性（63％）和不良事件发生率（47％）是决定治疗的最重要因素。22％（22％）的CSU患者报告80-100％是奥马珠单抗的完全缓解者；34％的患者倾向于增加频率（q2周），对于部分或无反应者，18%的人优选增加剂量(600毫克每4周)。UAS7,UCT,和CU-QoL用于评估CSU的55%，29%,25%的受访者，分别。自身免疫性甲状腺疾病（62%），甲状腺异常(43%)和过敏性鼻炎(35%)是最常见的合并症.
■由于安全性，大多数临床医生偏爱奥马珠单抗而不是其他潜在的治疗方法。尽管年轻的临床医生更有可能开出奥马珠单抗，成本和处方是主要障碍。只有22%的受访者报告80%或更多的患者对奥马珠单抗有完全缓解，表明需要新的CSU疗法。
